ClinicalTrials.gg
RecruitingNCT07352423Updated Nov 5, 2026

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants

A Phase 1 interventional study of ALXN2230 and Placebo in Healthy Adult Participants, sponsored by Alexion Pharmaceuticals, Inc.. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 5, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the safety and tolerability of single subcutaneous (SC) doses of ALXN2230 in healthy participants.

Read the detailed description

Part A of this study is expected to enroll approximately 40 participants (30 on ALXN2230 and 10 on placebo) across 5 cohorts and Part B is expected to enroll approximately 8 participants (6 on ALXN2230 and 2 on placebo) in 1 cohort.

02

Conditions studied

  • Healthy Adult Participants

Keywords

  • ALXN2230
  • Healthy Participants
  • Pharmacodynamics
  • Pharmacokinetics
  • PK
  • PD
  • Immunogenicity
  • First in Human
  • Single Ascending Dose
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Baseline immunoglobulin G (IgG) concentrations ≥ 1000 milligrams per deciliter (mg/dL) and ≤ 1600 mg/dL at Screening.
  • Antibody titers for Tetanus toxoid (≥ 0.1 International Units per milliliter (IU/mL)) at Screening.
  • Nonsmokers and not using any nicotine-containing products. A nonsmoker is defined as an individual who has abstained from smoking for at least 1 year prior to Screening.
  • within the range 18 to 32 kilograms per square meter (kg/m2), inclusive; with body weight ≥ 50 kilograms (kg).

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
  • Abnormal blood pressure (BP) (resting BP not to exceed 140/80 mmHg and no less than 90/60 mmHg) at screening
  • Participants who have history of allergy or to in ALXN2230.
  • History of unexplained, recurrent infection, or infection requiring treatment with systemic antibiotics within 90 days prior to dosing on Day 1.
  • Pregnant or breastfeeding females are excluded from the clinical study.
  • Participants with known immunological disorders.
  • Lymphoma, leukemia, breast cancer or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 5 years.
  • > 1.0 × (ULN)
  • > 1.0 × ULN
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with exception for Gilbert's syndrome).
  • > 450 millisecond (msec) for male participants or > 470 msec for female participants.
  • Significant blood loss (including blood donation [> 500 mL]) or had a transfusion of any blood product within 12 weeks prior to dosing or plan 1 within 4 weeks after the end of the study.

Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants will be enrolled across multiple cohorts and will receive a single dose of placebo.

    Drug: Placebo

  • Experimental
    ALXN2230

    Participants will be enrolled across multiple cohorts and will receive a single dose of ALXN2230.

    Drug: ALXN2230

Interventions

  • DrugALXN2230

    Participants will receive ALXN2230 via SC injection. Optional cohort will receive ALXN2230 via SC infusion.

  • DrugPlacebo

    Participants will receive placebo via SC injection. Optional cohort will receive placebo via SC infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    Time frame: Day 1 up to Day 113

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of ALXN2230

    Time frame: Day 1 up to Day 113

  2. Time to Cmax (Tmax) of ALXN2230

    Time frame: Day 1 up to Day 113

  3. Area Under the Concentration-time Curve from Time 0 to the Last Quantifiable Concentration (AUCt) of ALXN2230

    Time frame: Day 1 up to Day 113

  4. Serum Concentration of Biomarkers

    Time frame: Day 1 up to Day 113

07

Study locations

1 of 1 sites recruiting
  • Research Site
    London, NW10 7EW, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a CSR synopsis and plain language summaries.

Supporting information: Clinical study report

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 16 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Aug 2027 and completion Dec 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 20, 2026
StartActual
Mar 26, 2026
Primary completionEst.
Aug 9, 2027was Dec 2026
CompletionEst.
Aug 9, 2027was Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 23, 2026→Aug 9, 2027
Nov 5, 2026
Study completion
Dec 23, 2026→Aug 9, 2027
Nov 5, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedAbnormal blood pressure (BP) (resting BP not to exceed 140/80 mmHg and no less than 90/60 mmHg). at screening
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 23, 2026→Aug 9, 2027
    Study completion Dec 23, 2026→Aug 9, 2027
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedAbnormal blood pressure (BP) (resting BP not to exceed 140/80 mmHg and no less than 90/60 mmHg). at screening
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07352423
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Mar 26, 2026
Primary completion
Aug 9, 2027 (estimated)
Completion
Aug 9, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Alexion Pharmaceuticals, Inc. (Sponsor)
Contact
clinicaltrials@alexion.com
1-855-752-2356

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion